View the latest campus policy, news, and information related to COVID-19.

Karl Griswold headshot

Karl Griswold

Associate Professor of Engineering

Karl Griswold featured

The Griswold Research Group is developing high-throughput screens for evolutionary protein engineering, new strategies for protein deimmunization, enhanced protein expression systems, and powerful antibacterial agents to treat drug-resistant infections. (Photo by John Sherman)

Education

  • BS, Chemistry, Southwest Texas State University 1995
  • PhD, Chemistry, University of Texas at Austin 2005

Research Interests

Protein engineering; directed evolution; biotherapeutics; applied biocatalysis; high throughput screening

Selected Publications

  • Scanlon, T.C., Dostal, S.M., Griswold, K.E. A High Throughput Screen for Antibiotic Drug Discovery. Biotechnology & Bioengineering (2013), [Epub ahead of print]; PMID: 23955804
  • Teneback, C.C., Scanlon, T.C., Wargo, M.J., Bement, J., Griswold, K.E., Leclair, L.W. Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrobial Agents and Chemotherapy (2013), 57(11), pp. 5559–5564
  • Lamppa, J.W., Tanyos, S.A., Griswold, K.E. Engineering Escherichia coli for Soluble Expression and Single Step Purification of Active Human Lysozyme. Journal of Biotechnology (2013), 164, pp. 1-8
  • Choi Y., Griswold K.E., Bailey-Kellogg C. Structure-based Redesign of Proteins for Minimal T cell Epitope Content. Journal of Computational Chemistry (2013), 34(10), pp. 879-891
  • Lamppa, J.W., Griswold, K.E. Alginate Lyase Exhibits Catalysis-Independent Biofilm Dispersion and Antibiotic Synergy. Antimicrobial Agents and Chemotherapy (2013), 57(1), pp. 137-145
  • Osipovitch, D.C., Parker, A.S., Makokha, C.D., Desrosiers, J., Kett, W.C., Moise, L., Bailey-Kellogg, C., Griswold, K.E. Design and Analysis of Immune-Evading Enzymes for ADEPT Therapy. Protein Engineering, Design & Selection (2012), 25(10), pp. 613-624

Awards

  • Wallace H. Coulter Foundation Early Career Translational Research Award in Biomedical Engineering (2008)
  • NIH Biotechnology Training Grant (2000-2003)
  • Royston M. Roberts - Regents Fellowship, University of Texas (1999)
  • DOW Chemical Foundation Scholar, Texas State University (1991-1995)
  • Presidential Upper Division Scholar, Texas State University (1994-1995)
  • ACS Polymer Education Committee Award for Organic Chemistry (1993)

Professional Activities

  • Member, AIChE
  • Member, ACS
  • Member, SIM
  • Member, ASEE

Courses

  • ENGS 58: Introduction to Protein Engineering
  • ENGG 260: Advances in Biotechnology

Patents

  • System and apparatus for porously-encapsulated magnetic-nanoparticle biosensors | 10,502,735
  • Deimmunized lysostaphin and methods of use | 10,358,636
  • Therapeutic charge engineered variants of lysozyme and methods for using same to treat infection | 9,074,201

Startups

Stealth Biologics
Co-Founder and CEO

Research Projects

  • Enzyme therapeutics

    Enzyme therapeutics

    Enzyme therapeutics are a potential means of addressing the emerging health care crisis resulting from drug resistant microbial pathogens. Efforts are focused on the redesign of antimicrobial proteins for enhanced bactericidal activity towards various clinically relevant targets. One facet of this work relates to complications associated with the genetic disease cystic fibrosis, and is being investigated in conjunction with the Cystic Fibrosis Foundation Research Development Program at The Geisel School of Medicine at Dartmouth.

  • Immunogenicity prediction

    Immunogenicity prediction

    Immunogenicity prediction is an important means to control the safety of protein drugs, which can be recognized by the patient's immune system as foreign, inducing an adaptive immune response that can cause significant toxicity. We are developing approaches in which the immunogenicity of proteins can be assessed in vitro using protein engineering tools.

  • Cellular engineering of protein expression hosts

    Cellular engineering of protein expression hosts

    Cellular engineering of protein expression hosts provides the ability to modify proteins in a site specific and controlled fashion—something increasingly important for the development of therapeutic proteins. We are developing methods by which cells are genetically engineered to incorporate sugars on a recombinant protein in a site-specific sequence dependent manner. Once a sugar is positioned on a given protein, conventional chemical modification such as PEGlylation can be used to further modify the protein and improve its therapeutic properties.

  • Protein engineering tools in immunology

    Protein engineering tools in immunology

    Protein engineering tools in immunology can be used as an unbiased and systematic means of identifying new targets, generating diagnostic and therapeutic reagents, and characterizing the basic biology of infectious disease.

Videos

Therapeutic Protein Research

Seminar: Molecular Engineering of WMD (Weapons of Microbial Destruction)

B&B: A high-throughput screen for antibiotic drug discovery

Seminar: Breaking the Pattern—Building Better Biotherapies

News